New pages

13:1313:13, 3 June 2026 Acoltremon (hist | edit) [10,327 bytes] Anum Ijaz (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{AIJ}} |aOrAn=a |drugClass=TRPM8 thermoreceptor agonist |indicationType=treatment |indication=the signs and symptoms of dry eye disease. |adverseReactions=instillation site pain (50%). |blackBoxWarningTitle='''TITLE''' |blackBoxWarningBody=''Condition Name:'' (Content) |fdaLIADAdult=====FDA-labeled Indications==== * TRYPTYR is indicated for the...")

14:2714:27, 2 June 2026 Telisotuzumab vedotin-tllv (hist | edit) [28,370 bytes] Anum Ijaz (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{AIJ}} |aOrAn=a |drugClass=a c-Met-directed antibody and microtubule inhibitor conjugate |indicationType=treatment |indication=adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression [≥50% of tumor cells with strong (3+) staining], as determined by an FDA-approved test, who have received a prior systemic therapy. |adverseReactions=were perip...")

13:3713:37, 25 May 2026 Avutometinib potassium and Defactinib hydrochloride (hist | edit) [35,103 bytes] Anum Ijaz (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{AIJ}} |genericName=Avutometinib and Defactinib |aOrAn=a |drugClass=combination of avutometinib and defactinib, each kinase inhibitors, |indicationType=treatment |indication=adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) who have received prior systemic therapy. |adverseReactions=laboratory abnormalities, were increased creatine phosphokinase, nausea, fatigue, increased aspartate aminotransferase...")
11:5511:55, 25 May 2026 Nipocalimab-aahu (hist | edit) [30,203 bytes] Anum Ijaz (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{AIJ}} |genericName=Nipocalimab |aOrAn=a |drugClass=neonatal Fc receptor blocker |indicationType=treatment |indication=generalized myasthenia gravis (gMG) in adult and pediatric patients 12 years of age and older who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive. |adverseReactions=respiratory tract infections, peripheral edema, and muscle spasms ( in patients with gMG treate...")

02:3402:34, 24 May 2026 Penpulimab (hist | edit) [42,564 bytes] Anum Ijaz (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{AIJ}} |genericName=Penpulimab |aOrAn=a |drugClass=programmed death receptor-1 (PD-1)-blocking antibody |indicationType=treatment |indication=* In combination with either cisplatin or carboplatin and gemcitabine for the first-line treatment of adults with recurrent or metastatic non-keratinizing nasopharyngeal carcinoma (NPC). * As a single agent for the treatment of adults with metastatic non-keratinizing NPC with disease progres...")

22:1122:11, 23 May 2026 Atrasentan (hist | edit) [23,500 bytes] Anum Ijaz (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{AIJ}} |genericName=Atrasentan |aOrAn=an |drugClass=endothelin receptor antagonist |indicationType=treatment |indication=in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) ≥ 1.5 g/g. |hasBlackBoxWarning=Yes |adverseReactions=peripheral edema and anemia (incidence >5%). |blackBoxWarningTitle=''' EMBRYO-FE...")

01:5301:53, 22 May 2026 Fitusiran (hist | edit) [36,754 bytes] Anum Ijaz (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{AIJ}} |aOrAn=an |drugClass=antithrombin-directed small interfering ribonucleic acid |indicationType=prophylaxis |indication=to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients aged 12 years and older with hemophilia A or B with or without factor VIII or IX inhibitors. |adverseReactions=viral infection, nasopharyngitis, and bacterial infection. |blackBoxWarningTitle='''<span style="co...")

14:0614:06, 21 May 2026 Gepotidacin (hist | edit) [42,400 bytes] Anum Ijaz (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |aOrAn=a |drugClass=triazaacenaphthylene bacterial type II topoisomerase inhibitor |indicationType=treatment |indication=of the following infections caused by susceptible microorganisms: * Uncomplicated urinary tract infections (uUTI) in female adult and pediatric patients 12 years of age and older weighing at least 40 kilograms (kg). * Uncomplicated Urogenital Gonorrhea: The recommended dosage of BLUJEPA is 3,000 mg (four 750 mg tablets)...") originally created as "Gepoticadin"

18:1818:18, 20 May 2026 Vimseltinib (hist | edit) [25,025 bytes] Anum Ijaz (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |aOrAn=a |drugClass=kinase inhibitor |indicationType=treatment |indication=adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause worsening functional limitation or severe morbidity. |adverseReactions=laboratory abnormalities are increased AST, periorbital edema, fatigue, rash, increased cholesterol, peripheral edema, face edema, decreased neutr...")

01:2201:22, 18 May 2026 Mirdametinib (hist | edit) [19,194 bytes] Anum Ijaz (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{AIJ}} |aOrAn=a |drugClass=kinase inhibitor |indicationType=treatment |indication=adult and pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas (PN) not amenable to complete resection. |adverseReactions=Ocular Toxicity, Left Ventricular Dysfunction, Dermatologic Adverse Reactions, and Embryo-Fetal Toxicity. |blackBoxWarningTitle='''<spa...")

Navigation menu